Annual report 2026

July 25, 2026 The Manager, The Manager, Bombay Stock Exchange Limited The National Stock Exchange of India Ltd., Corporate Relationship Department Exchange Plaza, P. J. Towers, Dalal Street, Bandra Kurla Complex, Bandra (E) Mumbai – 400001. Mumbai -400051 BSE Scrip Code No. 524280 NSE Symbol: KOPRAN Dear Sir/Madam, Sub: Submission of Annual Report for the FY 2025-26 (Including Notice of 67th Annual General Meeting). This is in reference to our letter dated July 16, 2026 informing you about the 67th Annual General Meeting (AGM) of the company which is scheduled to be held on Tuesday, August 18, 2026 at 11.30 a.m. (IST) through Video Conferencing (“VC”) / Other Audio-Visual Means (“OAVM”). Pursuant to Regulation 34(1) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we enclose the copy of the Annual Report for the financial year 2025-26, along with the Notice of 67th Annual General Meeting (AGM) for your records. The said Annual Report is being sent today to the Members through electronic mode, whose email ids are registered with the Company/ Depositories. The same is also made available on the company’s website at QR Code Kopran Limited – Annual Report FY 2025-26. We request you to take above information on records. Regards, For Kopran Limited Sunil Sodhani Company Secretary & Compliance Officer Membership No. FCS 3897 KOPRAN LTD.: Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. P. B. No. 9917, Tel.: (022) 4366 1111 Fax: (022) 2495 0363 Website: www.kopran.com CIN – L 24230 MH 1958 PLC 011078. Email: cs@kopran.com Works: • Village Savroli, Taluka: Khalapur, District: Raigad - 410 202. Tel.: (02192) 274500 / 335 / 337• Fax: (02192) 274025 Annual Report 2025-26 Poised for the Next Innovating. Integrating. Diversifying. For over six decades, we have What’s built a strong foundation in the pharmaceutical industry through quality, reliability and continuous inside progress. As global healthcare evolves, we remain focused on strengthening our capabilities and creating sustainable value through innovation, integration and diversification. pg. 02-19 pg. 20-80 Corporate Overview Statutory Reports 02 About Us 20 Directors’ Report 04 Business Overview 28 Management Discussion and Analysis 06 Financial Highlights 46 Report on Corporate Governance Poised 07 Geographical Presence 72 Notice 08 Operating Environment 10 Research and Development for the Next 12 Manufacturing Excellence pg. 81-213 14 Quality and Safety Management 15 Our People Financial Statements 16 Stakeholder Engagement 81 Standalone Financial Statements 17 Governance 148 Consolidated Financial Statements 18 Board of Directors 19 Corporate Information Innovation continues to shape our journey across the pharmaceutical value chain. Through our R&D capabilities, we develop differentiated products, advance process improvements and respond to evolving market requirements. Our scientific expertise enables us to deliver quality healthcare solutions across diverse therapeutic segments and geographies. Integration remains central to our growth strategy. Our presence across Active As we move forward, Pharmaceutical Ingredients (APIs) and we remain committed Formulations enables us to leverage synergies, enhance operational excellence and strengthen to advancing with customer partnerships. Supported by robust purpose, agility and manufacturing capabilities and quality Forward-looking statements systems, we serve regulated and emerging excellence. With strong Some information in this report may contain forward-looking statements which include statements regarding Company’s markets worldwide. expected financial position and results of operations, business plans and prospects etc. and are generally identified by foundations, trusted To view or download this Report forward-looking words such as “believe,” “plan,” “anticipate,” “continue,” “estimate,” “expect,” “may,” “will” or other similar online, scan the QR Code words. Forward-looking statements are dependent on assumptions or basis underlying such statements. We have chosen Diversification strengthens our ability to capabilities and a For more investor-related these assumptions or basis in good faith, and we believe that they are reasonable in all material respects. However, we expand our portfolio, access new opportunities caution that actual results, performances or achievements could differ materially from those expressed or implied in such future-ready approach, information, please visit: and build resilient growth platforms. Our focus forward-looking statements. We undertake no obligation to update or revise any forward-looking statement, whether as a https://www.kopran.com/investors/ result of new information, future events, or otherwise. on specialised products, global partnerships we are poised for the and market expansion positions us to address next phase of growth. evolving healthcare needs. About Us Rooted in Experience. Driven by Progress. Established in 1958, we are an integrated pharmaceutical company with a strong global presence. We develop, manufacture and supply Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs). Mission Over six decades, we have strengthened capabilities across the pharmaceutical value chain. This foundation enables us to serve To create a sustainable regulated and emerging markets with a growth business through an integrated approach diversified portfolio. to product development, adoption of the latest technologies and highest We operate our Formulations business 1958 standards of quality and through Kopran Limited and our API manufacturing practices. business through Kopran Research Legacy of Excellence Laboratories Limited (KRLL), our wholly owned subsidiary. This integrated API + FDF structure strengthens operational synergies and enhances quality oversight. Integrated Business Model It also improves efficiency, agility and value creation across our operations. Our state-of-the-art manufacturing facilities and multiple regulatory Manufacturing Facilities accreditations reflect our commitment to excellence. We deliver high-quality Quality pharmaceutical products to customers Culture across more than 50 countries. Technology Through continuous innovation, Driven Manufacturing strategic integration and portfolio Creating a diversification, we remain responsive to Positive evolving market needs. Global and Productive As we look ahead, we continue Regulated and strengthening our capabilities and Emerging Markets Work Culture. expanding our global footprint. We remain committed to delivering reliable and affordable healthcare solutions. Together, these efforts position us Countries Served to create sustainable value for our stakeholders and remain poised for the next phase of growth. 02 03 Corporate Overview 02-19 Statutory Reports pg.20-80 Financial Statements 81-213 Kopran Limited Annual Report 2025-26 Business Overview Creating Value Across the Segment-wise Revenue Mix (FY2025-26) Pharmaceutical Value Chain *Includes smaller product categories with individual revenue below ₹100 lakhs. Market-wise Revenue Mix (FY2025-26) (₹ Lakhs) Product Segment Revenue We operate through Carbapenem 18,977 two complementary Macrolide 6,081 Multi-Purpose Product Segments Anti Infective 4,580 pharmaceutical business Manufacturing Facilities Neuromodulator 2,551 Anti-Hypertensive verticals comprising Sterile Cephalosporin 2,315 Cardiac Macrolide Antibiotic Urological 1,675 Active Pharmaceutical Macrolides Neuromodulator Intermediate 394 Ingredients (APIs) and Granules Anti Hypertensive 392 Urological Formulations. Together, Sterile Carbapenems Anti Diabetic 142 Anti-Infective / Anti-Acne CNS 129 they strengthen our Multipurpose Plants Sterile Carbapenem Miscellaneous* 99 presence across the Pilot Plants Total 37,335 Sterile Cephalosporin pharmaceutical value Kilo Lab Anti Thrombotic chain. We develop Research & Development and Anti-asthmatic Formulations Business Prod [Showing first 8,000 characters — download PDF for full document]